Skip to main content
Clinical Trials/NCT03537911
NCT03537911
Completed
Not Applicable

Cognitive Support Program for Patients With Brain Metastases

University Health Network, Toronto1 site in 1 country18 target enrollmentJuly 1, 2017
ConditionsMetastases, CNS

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metastases, CNS
Sponsor
University Health Network, Toronto
Enrollment
18
Locations
1
Primary Endpoint
Functional Assessment of Cancer Therapy - Cognitive
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study evaluates the feasibility and preliminary efficacy of a brief cognitive-behavioural program designed to improve cognitive functioning in people with brain metastases.

Detailed Description

Cognitive impairments (such as problems with attention, executive functions, memory and language abilities) are common in people with brain metastases as a result of disease and/or treatment effects. These impairments can significantly limit functional independence, participation in valued roles and activities, and overall quality of life. Building on research in other cognitively-impaired populations, we designed a brief, structured, patient-centered Cognitive Support Program (CSP) for brain metastases patients, who have the option of participating with a caregiver. Program contents include supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration). This prospective, single-arm study will enroll 24 brain metastases patients to evaluate the feasibility and preliminary efficacy of the CSP. A battery of outcome measures is administered (1) prior to intervention, (2) after completing the CSP, and (3) after an additional 3 months to evaluate longer-term outcomes. Feasibility assessment will include program retention and adherence. Reliable change analyses will examine treatment effects, with regression analyses to explore moderating effects of select patient, disease and treatment factors (e.g., severity of baseline cognitive impairment, number of brain lesions, cranial radiation dose and distribution). Results of this trial will inform further development and implementation of evidence-based supportive care for cognitively-impaired brain metastases patients.

Registry
clinicaltrials.gov
Start Date
July 1, 2017
End Date
November 28, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • age 18 or older
  • able to provide informed consent to all procedures
  • diagnosis of one or more brain metastases, with primary cancer outside the CNS
  • indication of cognitive deficits from self-report and/or cognitive testing
  • interest in participating in a cognitive rehabilitation program
  • able to complete study activities

Exclusion Criteria

  • concurrent non-cancer-related neurological or major psychiatric disorder or other medical condition suspected to influence cognition

Outcomes

Primary Outcomes

Functional Assessment of Cancer Therapy - Cognitive

Time Frame: Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training)

Multi-domain cognitive symptom questionnaire completed at each time point. Raw scores are converted to z-scores (M = 0, SD = 1, higher scores = better functioning) according to published criteria, and change from baseline to post-training and to 3-month follow-up calculated by subtraction.

Secondary Outcomes

  • Hopkins Verbal Learning Test - Revised(Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training))
  • Frontal Systems Behavior Scale(Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training))
  • Controlled Oral Word Association Test(Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training))
  • Trail Making Test(Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training))
  • Wechsler Digit Span Test(Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training))
  • Functional Assessment of Cancer Therapy - Brain(Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training))
  • Illness Intrusiveness Rating Scale(Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training))
  • BADS Zoo Map Test(Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training))
  • Positive and Negative Affect Schedule(Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training))
  • Hospital Anxiety and Depression Scale(Baseline; 2 months (0-2 weeks post-training); 5 months (3 months post-training))

Study Sites (1)

Loading locations...

Similar Trials